Antisense Oligonucleotide Therapies
Open Access
- 9 November 2014
- journal article
- review article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 43 (1), 78-89
- https://doi.org/10.1177/0192623314551840
Abstract
Many antisense oligonucleotides (ASOs) from several classes of molecules are currently in drug development. Despite over 20 years of pharmaceutical research, few ASOs have been marketed due to problems with clinical efficacy or preclinical toxicologic challenges. However, a number of recent developments have renewed interest in this class including the registration of mipomersen, the advent of successful screening strategies to eliminate more toxic molecules, and new understanding of the risks of off-target nucleotide binding and mitigation of potential off-target effects. Recent advances in backbone chemistries, conjugation to other moieties, and new delivery systems have allowed better tissue penetration, enhanced intracellular targeting, and less frequent dosing, resulting in fewer toxicities. While these new developments provide invigorated interest in these platforms, a few lingering challenges and preclinical/clinical toxicity issues remain to be completely resolved, including: (1) proinflammatory effects (vasculitis/inflammatory infiltrates); (2) nephrotoxicity and hepatotoxicity unrelated to lysosomal accumulation; and (3) thrombocytopenia. Recent investigative work by several laboratories have helped elucidate mechanisms for these issues, allowing a better understanding of the clinical relevance and implications of particular toxicities. It is important for toxicologists, pathologists, and regulatory reviewers to be familiar with new developments in the ASO field and their implications, as a greater number of new types of antisense molecules undergo preclinical toxicity testing.Keywords
This publication has 50 references indexed in Scilit:
- Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification PatternNucleic Acid Therapeutics, 2013
- Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNAMolecular Therapy Nucleic Acids, 2012
- Silencing of microRNA families by seed-targeting tiny LNAsNature Genetics, 2011
- Targeted nanoparticles enhanced flow electroporation of antisense oligonucleotides in leukemia cellsBiosensors and Bioelectronics, 2010
- Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based MechanismsMolecular Therapy, 2010
- Crosstalk pathways between Toll-like receptors and the complement systemTrends in Immunology, 2010
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2008
- Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cellsNucleic Acids Research, 2007
- Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animalsNucleic Acids Research, 2006
- Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound HeterozygoteAmerican Journal of Human Genetics, 2006